Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease ...
The agency OK’d an artificial vessel to restore blood flow in patients, even though its own scientists flagged questionable ...
Kera, who is in her 40s but is often mistaken for a woman in her 20s, has shared her secret to maintaining a youthful ...
ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...
Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...
FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably ...
MyChesCo on MSN1d
FDA Unveils Life-Changing Drug, Urgent Device Alert, and Revolutionary Tech to Protect Your HealthThe U.S. Food and Drug Administration (FDA) has announced a series of critical updates this week, reflecting its ongoing ...
Zacks Investment Research on MSN3d
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The evolution of the safety and effectiveness evaluation of endovascular grafts intended for abdominal aortic aneurysm repair ...
More than 150,000 Americans could get diagnosed with colorectal cancer this year, but lifestyle changes can lower your risk, ...
For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback